ABEONA THERAPEUTICS INC. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
ABEONA THERAPEUTICS INC. (ABEO) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $319.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-08-13
- 2026-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $319.00K.
- 2026-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $484.00K.
- 2025-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $676.00K.
- 2025-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $874.00K.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2026-06-30 | $319.00K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $484.00K 10-Q · filed 2026-05-13 |
| 2025-12-31 | $676.00K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $874.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $983.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $1.17M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $1.39M 10-K · filed 2026-03-17 |
| 2024-09-30 | $1.60M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $1.81M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $2.00M 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |